Lumibird Medical has installed the first clinical prototype of its Doppler holography system at the Hôpital National des Quinze-Vingts – a major step toward in transforming retinal imaging and vascular diagnostics.
This milestone is the result of over 20 years of collaborative research, led by the Institut Langevin (ESPCI Paris – PSL – CNRS), and the first major achievement of the HoloDoppler project, supported by Bpifrance through the France 2030 initiative. Lumibird Medical confirms that a second protype will be installed in June at the Hôpital Fondation Adolphe Rothschild in Paris.
This system enables real-time, non-invasive measurement of retinal blood flow using near-infrared light — unlocking new potential in the diagnosis and monitoring of glaucoma, AMD, diabetic retinopathy, and beyond, into overall vascular health. This is more than a technological leap — it’s a concrete move from lab to clinic, powered by open science and high-performance imaging.
HoloDoppler aligns with our strategy to strengthen our portfolio of therapeutic lasers (glaucoma, diabetes) with a range of high-performance and strong value-added imaging equipment. At Lumibird Medical, we are committed to making Doppler holography a widely accessible, transformative tool in eye care and vascular medicine.